Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
Human CellExp Fas Ligand/FasL, human recombinant protein
FASLG, ALPS1B, APT1LG1, CD178, CD95-L, CD95L, FASL, TNFSF6, Fas ligand
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | P48023 |
|---|---|
| Calculated MW | This protein is fused with 6×His tag at N-terminus, has a calculated MW of 17.7 kDa. The predicted N-terminus is His. Protein migrates as 25-32 kDa in reduced SDS-PAGE due to glycosylation. |
| Gene ID | 356 |
|---|---|
| Gene Symbol | FASLG |
| Other Names | FASLG, ALPS1B, APT1LG1, CD178, CD95-L, CD95L, FASL, TNFSF6, Fas ligand |
| Gene Source | Human |
| Source | HEK293 cells |
| Assay&Purity | SDS-PAGE; ≥95% |
| Assay2&Purity2 | N/A; |
| Recombinant | Yes |
| Results | Measured by its ability to induce apoptosis of Jurkat human acute T cell leukemia cells. The ED50 for this effect is typically 0.1-1.5 ng/mL in the presence of 10 µg/mL of a crosslinking antibody Mouse Anti poly-Histidine Monoclonal Antibody. |
| Target/Specificity | Fas Ligand/FasL |
| Application Notes | Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C. |
| Format | Lyophilized |
| Storage | -20°C; Lyophilized from 0.22 µm filtered solution in 50 mM tris, 100 mM glycine, pH 7.0. Normally Mannitol or Trehalose is added as protectants before lyophilization. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Fas ligand also known as FasL, CD178, CD95L, or TNFSF6, is a homotrimeric type-II transmembrane protein that belongs to the tumor necrosis factor (TNF) family. Its binding with its receptor induces apoptosis. Fas ligand/receptor interactions play an important role in the regulation of the immune system and the progression of cancer. Mature human Fas Ligand consists of a 179 amino acid (aa) extracellular domain (ECD), a 22 aa transmembrane segment, and a 80 aa cytoplasmic domain. Within the ECD, human Fas Ligand shares 81% and 78% aa sequence identity with mouse and rat Fas Ligand, respectively. Apoptosis triggered by Fas-Fas ligand binding plays a fundamental role in the regulation of the immune system. Its functions include T-cell homeostasis, cytotoxic T-cell activity, immune privilege, maternal tolerance, tumor counterattack. Defective Fas-mediated apoptosis may lead to oncogenesis as well as drug resistance in existing tumors. Germline mutation of Fas is associated with autoimmune lympho proliferative syndrome (ALPS), a childhood disorder of apoptosis.
References
Alderson M.,et al.J. Exp. Med. 181:71-77(1995).
Takahashi T.,et al.Int. Immunol. 6:1567-1574(1994).
Schaetzlein C.E.,et al.Submitted (JUN-1995) to the EMBL/GenBank/DDBJ databases.
Mita E.,et al.Biochem. Biophys. Res. Commun. 204:468-474(1994).
Zeytun A.,et al.Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
